Vitamin D restores angiogenic balance and decreases tumor necrosis factor-α in a rat model of pre-eclampsia

Journal of Obstetrics and Gynaecology Research

Volumn 43, Issue 1, 2017, Pages 42-49

  Song, Jing ^a,b   Li, Yue ^c   An, Ruifang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c Hospital of Heilongjiang Province   (China)

Author keywords

pregnancy induced hypertension; soluble FMS like tyrosine kinase 1; tumor necrosis factor ; vascular endothelial growth factor; vitamin D

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 6; MALONALDEHYDE; PROTEIN CARBONYL; PROTEIN TYROSINE KINASE; SOLUBLE FMS LIKE TYROSINE KINASE 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VITAMIN D; AUTACOID; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANGIOGENIC BALANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; MOLECULAR DYNAMICS; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PREECLAMPSIA; RAT; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; WEIGHT GAIN; ANIMAL; BLOOD PRESSURE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; METABOLISM; PREGNANCY; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; FEMALE; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; OXIDATIVE STRESS; PRE-ECLAMPSIA; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITAMIN D;

EID: 85008873394     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/jog.13186     Document Type: Article

References (48)

1. Henao DE, Saleem MA. Proteinuria in preeclampsia from a podocyte injury perspective. Curr Hypertens Rep 2013; 15: 600–605.
2. Chaturvedi S, Randive B, Mistry N. Availability of treatment for eclampsia in public health institutions in Maharashtra, India. J Health Popul Nutr 2013; 31: 86–95.
3. Jido TA, Yakasai IA. Preeclampsia: A review of the evidence. Ann Afr Med 2013; 12: 75–85.
4. Fowles ER, Walker LO, Marti CN et al. Relationships among maternal nutrient intake and placental biomarkers during the 1st trimester in low-income women. Arch Gynecol Obstet 2012; 285: 891–899.
5. Bodnar LM, Catov JM, Simhan HN, Holick MF, Powers RW, Roberts JM. Maternal vitamin D deficiency increases the risk of preeclampsia. J Clin Endocrinol Metab 2007; 92: 3517–3522.
6. Tabesh M, Salehi-Abargouei A, Tabesh M, Esmaillzadeh A. Maternal vitamin D status and risk of pre-eclampsia: A systematic review and meta-analysis. J Clin Endocrinol Metab 2013; 98: 3165–3173.
7. Wei SQ, Qi HP, Luo ZC, Fraser WD. Maternal vitamin D status and adverse pregnancy outcomes: A systematic review and meta-analysis. J Matern Fetal Neonatal Med 2013; 26: 889–899.
8. Freeman DJ, McManus F, Brown EA et al. Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension 2004; 44: 708–714.
9. Llurba E, Crispi F, Verlohren S. Update on the pathophysiological implications and clinical role of angiogenic factors in pregnancy. Fetal Diagn Ther 2015; 37: 81–92.
10. Santos TC, Oliveira MF, Papa PC, Dantzer V, Miglino MA. VEGF system expression by immunohistochemistry and real-time RT-PCR study on collared peccary placenta. Theriogenology 2014; 82: 834–843.
11. Roy S, Dhobale M, Dangat K, Mehendale S, Lalwani S, Joshi S. Differential oxidative stress levels in mothers with preeclampsia delivering male and female babies. J Matern Fetal Neonatal Med 2015; 28: 1973–1980.
12. Terlecky SR, Terlecky LJ, Giordano CR. Peroxisomes, oxidative stress, and inflammation. World J Biol Chem 2012; 3: 93–97.
13. Campos-Canas J, Romo-Palafox I, Albani-Campanario M, Hernandez-Guerrero C. An imbalance in the production of proinflammatory and anti-inflammatory cytokines is observed in whole blood cultures of preeclamptic women in comparison with healthy pregnant women. Hypertens Pregnancy 2014; 33: 236–249.
14. Szarka A, Rigo J Jr, Lazar L, Beko G, Molvarec A. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 2010; 11: 59.
15. Zhang Y, Gu Y, Li H, Lucas MJ, Wang Y. Increased endothelial monolayer permeability is induced by serum from women with preeclampsia but not by serum from women with normal pregnancy or that are not pregnant. Hypertens Pregnancy 2003; 22: 99–108.
16. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011; 7: 327–340.
17. Khong Y, Brosens I. Defective deep placentation. Best Pract Res Clin Obstet Gynaecol 2011; 25: 301–311.
18. Rajakumar A, Doty K, Daftary A, Harger G, Conrad KP. Impaired oxygen-dependent reduction of HIF-1alpha and -2alpha proteins in pre-eclamptic placentae. Placenta 2003; 24: 199–208.
19. Wintergerst ES, Maggini S, Hornig DH. Contribution of selected vitamins and trace elements to immune function. Ann Nutr Metab 2007; 51: 301–323.
20. Faulkner JL, Cornelius DC, Amaral LM et al. Vitamin D supplementation improves pathophysiology in a rat model of preeclampsia. Am J Physiol Regul Integr Comp Physiol 2016; 310: R346–R354.
21. Kemse NG, Kale AA, Joshi SR. A combined supplementation of omega-3 fatty acids and micronutrients (folic acid, vitamin B12) reduces oxidative stress markers in a rat model of pregnancy induced hypertension. PLoS One 2014; 9: e111902.
22. Laresgoiti-Servitje E. A leading role for the immune system in the pathophysiology of preeclampsia. J Leukoc Biol 2013; 94: 247–257.
23. Zhang P, Qi YX, Yao QP et al. Neuropeptide Y stimulates proliferation and migration of vascular smooth muscle cells from pregnancy hypertensive rats via Y1 and Y5 receptors. PLoS One 2015; 10: e0131124.
24. Geusens N, Verlohren S, Luyten C et al. Endovascular trophoblast invasion, spiral artery remodelling and uteroplacental haemodynamics in a transgenic rat model of pre-eclampsia. Placenta 2008; 29: 614–623.
25. Novakovic B, Sibson M, Ng HK et al. Placenta-specific methylation of the vitamin D 24-hydroxylase gene: Implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface. J Biol Chem 2009; 284: 14838–14848.
26. Huppertz B. Placental origins of preeclampsia: Challenging the current hypothesis. Hypertension 2008; 51: 970–975.
27. Ullah MI, Koch CA, Tamanna S, Rouf S, Shamsuddin L. Vitamin D deficiency and the risk of preeclampsia and eclampsia in Bangladesh. Horm Metab Res 2013; 45: 682–687.
28. Palacios C, De-Regil LM, Lombardo LK, Pena-Rosas JP. Vitamin D supplementation during pregnancy: Updated meta-analysis on maternal outcomes. J Steroid Biochem Mol Biol 2016; DOI:10.1016/j.jsbmb.2016.02.008. [Epub ahead of print].
29. Gad HI. The potential role of anti tumor necrosis factor-alpha antibodies on some renal functions and vasoregulatory factors in preeclamptic pregnant Wistar rats. Saudi Med J 2013; 34: 490–496.
30. Zhou Q, Shen J, Zhou G, Shen L, Zhou S, Li X. Effects of magnesium sulfate on heart rate, blood pressure variability and baroreflex sensitivity in preeclamptic rats treated with L-NAME. Hypertens Pregnancy 2013; 32: 422–431.
31. de Moura RS, Resende AC, Moura AS, Maradei MF. Protective action of a hydroalcoholic extract of a vinifera grape skin on experimental preeclampsia in rats. Hypertens Pregnancy 2007; 26: 89–100.
32. Gairard A, Lopez-Miranda V, Pernot F et al. Effect of i1 imidazoline receptor agonist, moxonidine, in nitric oxide-deficient hypertension in pregnant rats. J Cardiovasc Pharmacol 2004; 43: 731–736.
33. Fernandez Celadilla L, Carbajo Rueda M, Munoz Rodriguez M. Prolonged inhibition of nitric oxide synthesis in pregnant rats: Effects on blood pressure, fetal growth and litter size. Arch Gynecol Obstet 2005; 271: 243–248.
34. Hashemipour S, Ziaee A, Javadi A et al. Effect of treatment of vitamin D deficiency and insufficiency during pregnancy on fetal growth indices and maternal weight gain: A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2014; 172: 15–19.
35. Levine RJ, Lam C, Qian C et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992–1005.
36. Molvarec A, Szarka A, Walentin S, Szucs E, Nagy B, Rigo J Jr. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertens Res 2010; 33: 892–898.
37. Cardenas-Mondragon MG, Vallejo-Flores G, Delgado-Dominguez J et al. Preeclampsia is associated with lower production of vascular endothelial growth factor by peripheral blood mononuclear cells. Arch Med Res 2014; 45: 561–569.
38. Kulkarni AV, Mehendale SS, Yadav HR, Kilari AS, Taralekar VS, Joshi SR. Circulating angiogenic factors and their association with birth outcomes in preeclampsia. Hypertens Res 2010; 33: 561–567.
39. Bayram M, Taskaya A, Bagriacik EU, Ilhan MN, Yaman M. The effect of maternal serum sFAS/sFASL system on etiopathogenesis of preeclampsia and severe preeclampsia. J Matern Fetal Neonatal Med 2012; DOI:10.3109/14767058.2012.722710. [Epub ahead of print].
40. Catarino C, Santos-Silva A, Belo L et al. Inflammatory disturbances in preeclampsia: Relationship between maternal and umbilical cord blood. J Pregnancy 2012; 2012: 684384.
41. Murphy SR, LaMarca BB, Parrish M, Cockrell K, Granger JP. Control of soluble fms-like tyrosine-1 (sFlt-1) production response to placental ischemia/hypoxia: Role of tumor necrosis factor-alpha. Am J Physiol Regul Integr Comp Physiol 2013; 304: R130–R135.
42. Afshari JT, Ghomian N, Shameli A et al. Determination of interleukin-6 and tumor necrosis factor-alpha concentrations in Iranian-Khorasanian patients with preeclampsia. BMC Pregnancy Childbirth 2005; 5: 14.
43. Ozler A, Turgut A, Sak ME et al. Serum levels of neopterin, tumor necrosis factor-alpha and interleukin-6 in preeclampsia: Relationship with disease severity. Eur Rev Med Pharmacol Sci 2012; 16: 1707–1712.
44. Kolling J, Scherer EB, da Cunha AA, da Cunha MJ, Wyse AT. Homocysteine induces oxidative-nitrative stress in heart of rats: Prevention by folic acid. Cardiovasc Toxicol 2011; 11: 67–73.
45. Shiraishi M, Haruna M, Matsuzaki M et al. Relationship between plasma total homocysteine level and dietary caffeine and vitamin B6 intakes in pregnant women. Nurs Health Sci 2014; 16: 164–170.
46. Gohil JT, Patel PK, Gupta P. Evaluation of oxidative stress and antioxidant defence in subjects of preeclampsia. J Obstet Gynaecol India 2011; 61: 638–640.
47. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006; 160: 1–40.
48. Hopkins MH, Fedirko V, Jones DP, Terry PD, Bostick RM. Antioxidant micronutrients and biomarkers of oxidative stress and inflammation in colorectal adenoma patients: Results from a randomized, controlled clinical trial. Cancer Epidemiol Biomarkers Prev 2010; 19: 850–858.